香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 （於百慕達註冊成立之有限公司） ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED 阿里健康信息技術有限公司 董事會欣然公佈，於2025年8月8日舉行之股東週年大會上，通告所載之全部決議 案已經股東以投票表決方式正式通過。 茲提述(i)阿里健康信息技術有限公司（「本公司」，連同其附屬公司統稱「本集團」）日 期為2025年7月10日之股東週年大會（「股東週年大會」）通告（「通告」）；及(ii)本公司 日期為2025年7月10日之通函（「通函」）。除文義另有所指外，本公告所用專有詞彙 與通函所界定者具有相同涵義。 股東週年大會結果 本公司董事（「董事」）會（「董事會」）欣然公佈，於2025年8月8日（星期五）上午十時三 十分假座香港銅鑼灣禮頓道8號香港銅鑼灣皇冠假日酒店28樓貴賓廳舉行之股東週 – 1 – （股份代號：00241） 於2025年8月8日舉行之 股東週年 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 致：香港交易及結算所有限公司 公司名稱: 阿里健康信息技術有限公司 (於百慕達註冊成立之有限公司) 呈交日期: 2025年8月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00241 | 說明 | | | | | | | | | 法定/註冊股份數目 | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | 20,000,000,000 | HKD | | 0.01 HKD | | 200,000,000 | | 增加 / 減少 (-) | | | 0 | | HKD | | 0 | | 本月底結存 | | 20,000,000,000 | HKD | | 0.01 HKD | | 200,000,000 | 本月底法定/註冊股本總額： HKD 200,000,000 第 1 頁 共 1 ...

Group 1 - The core viewpoint of the article highlights the performance of Alibaba Health, which saw a stock price increase of 2.04% to 5.01 CNY per share, with a trading volume of 363 million CNY as of August 5 [1] - Alibaba Health is the flagship healthcare platform of Alibaba Group, focusing on self-operated pharmaceutical business, e-commerce platform business, and digital healthcare services [1] - The company leverages advanced digital technology and operational capabilities to provide accessible, efficient, and safe healthcare services to millions of families, creating an integrated online and offline pharmaceutical health service platform [1] Group 2 - As of the 2024 annual report, Alibaba Health reported total revenue of 30.598 billion CNY and a net profit of 1.432 billion CNY [2]

Market Performance - The CSI Cloud Computing and Big Data Theme Index increased by 1.2% [1] - The CSI Artificial Intelligence Theme Index rose by 0.5% [1] - The National Robot Industry Index decreased by 0.3% [1] - The Hang Seng Hong Kong Stock Connect Innovative Drug Index fell by 1.2% [1] - The CSI New Energy Index dropped by 3.1% [1] Company Developments - Alibaba Health launched an AI medical assistant named "Hydrogen Atom," which integrates millions of core medical journal articles and supports authoritative guideline access, semantic search, AI summarization, full-text translation, and intelligent Q&A [1] - The AI assistant is designed to help clinical medical workers and researchers quickly find necessary information, enhancing medical learning and research efficiency [1] Index Overview - The Artificial Intelligence ETF tracks the CSI Artificial Intelligence Theme Index, which comprehensively covers the AI industry chain, including upstream infrastructure, midstream models, and downstream applications [2] - The Robot ETF tracks the National Robot Industry Index, which covers the entire robot industry chain, with humanoid robots making up 53% of the index [2] - The Cloud Computing ETF tracks the CSI Cloud Computing and Big Data Theme Index, focusing on the cloud computing industry and related services [3] - The Innovative Drug ETF tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Index, which includes stocks involved in innovative drug research, development, and production [3] - The New Energy ETF tracks the CSI New Energy Index, covering the new energy industry chain, including lithium batteries, photovoltaics, wind power, hydropower, and nuclear power [3]

7月31日，阿里健康(00241)盘中下跌2.02%，截至13:17，报4.86元/股，成交3.04亿元。 本文源自：金融界 作者：行情君 阿里健康信息技术有限公司是阿里巴巴集团的医疗健康旗舰平台，主营业务包括医药自营业务、医药电 商平台业务、医疗健康及数字化服务业务。公司依托领先的数字技术和运营能力，为亿万家庭提供普惠 便捷、高效安全的医疗健康服务，打造出线上线下一体化的医药健康品服务平台。 截至2024年年报，阿里健康营业总收入305.98亿元、净利润14.32亿元。 ...

Group 1 - The Hong Kong internet healthcare stocks have surged, with Ping An Good Doctor leading the rise with an increase of nearly 9%, reaching a new high, followed by Alibaba Health with over 4% and JD Health with 3.4% [1] - The internet healthcare industry is experiencing multiple favorable developments, including policy support, technological innovation, market performance, and corporate collaboration [1] - The National Medical Products Administration released measures to support the innovation of high-end medical devices, focusing on AI imaging diagnosis, surgical robots, and brain-machine interfaces, with a goal to accelerate the establishment of relevant technical standards by July 2025 [1] Group 2 - Beijing's "AI + Pharmaceutical Health" action plan aims to build an "AI + Pharmaceutical Health" innovation ecosystem by 2027, promoting the implementation of over 30 core technologies and innovative products [1] - Analysts indicate that the internet healthcare industry is entering a rapid development phase driven by policies, technology, capital, and market demand, with significant growth potential in AI diagnosis, telemedicine, and digital therapeutics [1]

港股科网股集体上涨，百度(09888.HK)、BOSS直聘(02076.HK)、快手(01024.HK)涨超3%，阿里健康 (00241.HK)、京东(09618.HK)、贝壳(02423.HK)涨超1%。 ...

Core Viewpoint - The article discusses the rapid growth and potential of AI in healthcare, highlighting its transformative impact on patient management and the healthcare system in China, while also addressing the challenges and limitations faced by AI technologies in this sector [2][4][10]. Group 1: AI in Healthcare Services - AI services are increasingly being adopted by patients for health management, with applications such as report interpretation and intelligent triage leading the trend [2][3]. - Major internet companies like JD Health, Alibaba Health, and Baidu Health are actively developing independent AI health management applications, indicating a competitive landscape [3][4]. - The AI health management market in China is projected to reach 25.9 trillion yuan by 2027, with a compound annual growth rate exceeding 20% [4]. Group 2: Impact on Traditional Healthcare - AI technologies are significantly changing the traditional healthcare system, allowing hospitals to serve a larger number of patients efficiently [5][10]. - AI can alleviate the burden on healthcare professionals by handling repetitive tasks, thus improving overall service efficiency [7][10]. - The integration of AI into healthcare aims to create a closed-loop system that connects various healthcare services, enhancing data collection and patient management [7][10]. Group 3: Challenges and Limitations - Despite the potential benefits, there are significant challenges in gaining public trust in AI healthcare solutions, with only 3.59% of people believing AI can fully replace doctors [13][14]. - The complexity of integrating AI into healthcare requires deep collaboration with medical professionals to ensure the accuracy and reliability of AI systems [14][15]. - Legal and regulatory challenges, particularly concerning data privacy and the definition of responsibility in AI applications, pose significant hurdles for the industry [15][16].

Core Insights - The Hong Kong pharmaceutical sector is experiencing a strong rally, with the China Securities Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index (930965) rising by 1.50% as of July 16, 2025, driven by significant gains in individual stocks such as Lijun Pharmaceutical (01513) up 11.16% and Green Leaf Pharmaceutical (02186) up 8.55% [1][2] - The introduction of a commercial health insurance innovative drug directory by the National Healthcare Security Administration on July 11, 2025, marks a significant development, allowing for the inclusion of high-innovation drugs that exceed basic insurance coverage [1][2] - The first innovative drug directory involving commercial insurance is expected to be launched within 2025, potentially creating a more favorable pricing environment compared to traditional medical insurance negotiations [2] Industry Summary - The Hong Kong Medical ETF (513700) has seen a 1.72% increase, marking its fourth consecutive rise, with the latest price reported at 0.65 yuan [1] - The index reflects the performance of 50 liquid and large-cap healthcare companies within the Hong Kong Stock Connect, with the top ten weighted stocks accounting for 59.44% of the index [2] - The commercial health insurance sector is anticipated to experience significant growth, with potential for premium and innovative drug payment scales to increase by several multiples in the long term [2]

Group 1 - The Hang Seng Index (HSI) shows a significant rebound, with bullish investors expecting it to rise to 25,000, supported by a recovery price of 24,020 for overnight bull certificates [1] - Alibaba (09988.HK) has potential upward movement, with bullish investors targeting a price of 130 HKD, while the stock closed at 113.5 HKD, reflecting a 6.97% increase [3] - Bilibili-W (09626.HK) has broken through the upper Bollinger Band at 182 HKD, closing at 184.9 HKD, indicating a "buy" signal with resistance levels at 194.5 HKD and 200 HKD [6] Group 2 - NetEase-S (09999.HK) shows signs of a rebound, with a "buy" signal and resistance levels at 216 HKD and 224 HKD, suggesting that options with a strike price around 220 HKD may be more favorable [9] - Sunny Optical Technology (02382.HK) is experiencing upward momentum, closing near the upper Bollinger Band at 76.4 HKD, with a strong buy signal and resistance levels at 78.4 HKD and 82.3 HKD [12] - Alibaba Health (00241.HK) has risen for six consecutive days, with resistance levels at 4.8 HKD and 5.13 HKD, and options with a strike price of 4.51 HKD are considered reasonable [15]